Instrument Inactif

Autres langues Anpath Group, Inc. OTC Bulletin Board

Actions

US03634J1060

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

03/05/24	Telix Pharmaceuticals (Us) Inc. a conclu l'acquisition de QSAM Biosciences, Inc. (OTCPK:QSAM) auprès de Checkmate Capital Group LLC, Strategic Planning Assets Limited et d'autres.	CI
20/03/24	QSAM Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

03/05/24	Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.
16/04/24	QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
20/03/24	QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
20/03/24	QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
07/02/24	QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
14/11/23	QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
14/11/23	Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.
13/11/23	QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
29/09/23	QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding
16/08/23	QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
14/08/23	QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23/06/23	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)
14/06/23	QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
14/06/23	QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
23/05/23	QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
23/05/23	QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center
16/05/23	QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
15/05/23	QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
26/04/23	QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
26/04/23	QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam
11/04/23	QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/04/23	QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer
05/04/23	QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
05/04/23	QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer
04/04/23	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)